Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signalling lymphocytic activation molecule (SLAM) family member 7 (SLAMF7), selectively kills SLAMF7-expressing myeloma cells through direct activation and engagement of the innate immune system, and thus might have clinical...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Lancet Haematol
Egile Nagusiak: Richardson, Paul G, Jagannath, Sundar, Moreau, Philippe, Jakubowiak, Andrzej J, Raab, Marc S, Facon, Thierry, Vij, Ravi, White, Darrell, Reece, Donna E, Benboubker, Lotfi, Zonder, Jeffrey, Tsao, L Claire, Anderson, Kenneth C, Bleickardt, Eric, Singhal, Anil K, Lonial, Sagar
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6871650/
https://ncbi.nlm.nih.gov/pubmed/26686406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(15)00197-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak